Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CC5-M52D9 | Mouse | Mouse CCR5 Protein, Flag,His Tag (Detergent) |
|
||
CC5-H52P5 | Human | Fluorescent Human CCR5 Full Length Protein (VLP) |
|
||
CHEK-ATP043 | Human | HEK293/Human CCR5 Stable Cell Line | |||
CC5-H52P3 | Human | Human CCR5 Full Length Protein (VLP) |
|
||
CC5-H52D1 | Human | Human CCR5 Protein, Flag,His Tag (Detergent) |
|
|
FACS assay shows that Anti-CCR5 antibody can bind to HEK293/Human CCR5 Stable Cell Line. HEK293/Human CCR5 Stable Cell Line was red line, Negative control HEK293 cells was grey line (QC tested).
Human CCR5, Flag,His Tag (Cat. No. CC5-H52D1) captured on CM5 chip via anti-His antibody can bind Anti-CCR5 antibody (Human IgG1) with an affinity constant of 0.0737 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).
Purified NA/LE Mouse Anti-Human CD195 (Clone: 2D7) (Mouse IgG2a) captured on CM5 chip via anti-mouse antibodies surface can bind Human CCR5, Flag,His Tag (Cat. No. CC5-H52D1) with an affinity constant of 7.51 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Maraviroc | MVC; UK-427857 | Approved | Viiv Healthcare | Celsentri, Selzentry | Mainland China | HIV Infections | Godecke Gmbh | 2007-08-06 | HIV Infections; Hypertriglyceridemia; Acquired Immunodeficiency Syndrome; Hematopoietic stem cell transplantation (HSCT); Hematologic Neoplasms; Kidney Diseases; Arthritis, Rheumatoid; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Stroke; AIDS Dementia Complex; Cardiovascular Diseases; Inflammation; Sarcoma, Kaposi | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
BMS-687681 | BMS-687681 | Phase 1 Clinical | Neoplasms | Details | |
Cenicriviroc mesylate/Tropifexor | LJC-242 | Phase 2 Clinical | Novartis Pharma Ag | Non-alcoholic Fatty Liver Disease | Details |
Thioraviroc | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | HIV Infections | Details | |
Anti-CCR5 monoclonal antibody (Human Genome Sciences) | HGS-1025 | Glaxosmithkline Plc | Details | ||
PF-04634817 | PF-4634817; PF-04634817; PF-46334817 | Pfizer Pharmaceuticals Ltd (China) | Details | ||
INCB-009471 | INCB-9471; INCB-009471 | Incyte Corp | Details | ||
AZD-5672 | AZD5672; AZD-5672 | Astrazeneca Plc | Details | ||
AGT 103-T | AGT 103-T | American Gene Technologies International Inc | Details | ||
Lamivudine/Maraviroc/Zidovudine | GSK-2838510 | Glaxosmithkline Plc | Details | ||
BMS-813160 | BMS-813160 | Phase 2 Clinical | Bristol-Myers Squibb Company | Pancreatic Neoplasms; Hyperplasia; Diabetic Nephropathies; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Hepatocellular | Details |
SB-728-HSC | SB-728-HSC; SB-728-HSPC; SB-728mR-HSPC | Phase 1 Clinical | Sangamo Biosciences | HIV Infections | Details |
Vicriviroc | SCH-D; MK-4176; SCH-417; Sch-417690 | Phase 2 Clinical | Merck & Co Inc | HIV Infections; Acquired Immunodeficiency Syndrome; Colorectal Neoplasms | Details |
SB-728-T | SB-728mR-T; SB-728-T | Phase 2 Clinical | Sangamo Biosciences | HIV Infections | Details |
Cenicriviroc mesylate | CCR5/CCR2 antagonist; TBR-652; CVC; TAK-652 | Phase 3 Clinical | Tobira Therapeutics Inc, Takeda Pharmaceutical Co Ltd | Prediabetic State; HIV Infections; Acquired Immunodeficiency Syndrome; Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease; Liver Cirrhosis; Coronavirus Disease 2019 (COVID-19); AIDS Dementia Complex; Cholangitis, Sclerosing; Hepatic Insufficiency; Obesity; Cognition Disorders | Details |
Leronlimab | PRO-140; PA-14; HuPRO-140 | Phase 3 Clinical | Cytodyn Inc | HIV Infections; Solid tumours; Non-alcoholic Fatty Liver Disease; Coronavirus Disease 2019 (COVID-19); Triple Negative Breast Neoplasms; Graft vs Host Disease | Details |
This web search service is supported by Google Inc.